LONDON — Leqembi, the Alzheimer’s treatment from Eisai and Biogen, has hit another roadblock reaching patients in Europe. In draft guidance, the U.K.’s cost-effectiveness watchdog
LONDON — Patients in England with a rare blood disorder will now be able to receive the world’s first CRISPR-based medicine, after drugmaker Vertex Pharmaceuticals
LONDON — An underwhelming earnings report and ongoing questions about increasing competition in the booming obesity medicine field sent Novo Nordisk’s shares down early Wednesday,
LONDON — U.S. regulators have authorized a cutting-edge treatment relying on T cells for a rare cancer that arises in the body’s soft tissues, extending
Jim Wilson, a leading gene therapy researcher who has persisted through the field’s ups and downs, is leaving his longtime academic home at the University
Greetings from London, with STAT reporter Andrew Joseph here filling in for Ed for the day. We’ve shifted to our afternoon version of a cup
For the first time, the world is starting to roll out malaria vaccines to children in sub-Saharan Africa. The story of the development of those
Malaria is one of our most ancient foes — and one of the wiliest. Caused by parasites that certain mosquitoes spread through their bites, malaria
LONDON — European regulators on Friday said that an Alzheimer’s therapy from Eisai and Biogen should be rejected, again diverging from their U.S. counterparts on
LONDON — In the booming field of weight loss drugs, Roche has been riding high in recent months, with back-to-back positive studies of two experimental